Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3925212 | 1.00 | MEN1 (0.41) | MEN1KMT2AHSD17B10TDP1CYP2C9 | |
| SCHEMBL12089542 | 0.87 | EIF4A3 (0.47) | MEN1KMT2AHSD17B10TDP1CYP2C9 | |
| SCHEMBL16398486 | 0.85 | HSD17B10 (0.43) | MEN1KMT2AHSD17B10TDP1CYP2C9 | |
| SCHEMBL31280455 | 0.85 | HSD17B10 (0.43) | MEN1KMT2AHSD17B10TDP1CYP2C9 | |
| SCHEMBL9853831 | 0.82 | HSD17B10 (0.58) | MEN1KMT2AHSD17B10TDP1CYP2C9 | |
| SCHEMBL3915626 | 0.81 | ALDH1A1 (0.42) | MEN1KMT2AHSD17B10SLC6A4UGT2B7 | |
| SCHEMBL21064545 | 0.81 | LMNA (0.45) | KMT2AHSD17B10CYP3A4HPGDKDM4E | |
| SCHEMBL13777032 | 0.81 | ALDH1A1 (0.42) | MEN1KMT2AHSD17B10SLC6A4UGT2B7 | |
| SCHEMBL14381820 | 0.79 | KDM4E (0.61) | MEN1KMT2AHSD17B10TDP1CYP2C9 | |
| SCHEMBL31085123 | 0.78 | UGT2B7 (0.40) | MEN1KMT2AHSD17B10TDP1UGT2B7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281086-A1 | 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281086-A1 | 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090181951-A1 | PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20090181951-A1 | PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
| WO-2007144637-A1 | 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144652-A2 | PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281086-A1 | 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS | PARP2, PARP3, PARP11 | MEN1 1711/4885KMT2A 973/4885HSD17B10 380/4885 |
| US-20090181951-A1 | PARP INHIBITORS | PARP2, PARP3, PARP1 | MEN1 808/4885KMT2A 2114/4885HSD17B10 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.